These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 18192943)

  • 1. Cardiovascular protection paradigms: is change on the horizon?
    Papademetriou V
    Rev Cardiovasc Med; 2007; 8(4):200-13. PubMed ID: 18192943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal medical management of peripheral arterial disease.
    Rice TW; Lumsden AB
    Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The SaM (Screening and Monitoring) approach to cardiovascular risk-reduction in primary care--cyclic monitoring and individual treatment of patients at cardiovascular risk using the electronic medical record.
    Rabinowitz I; Tamir A
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):56-62. PubMed ID: 15703507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction.
    Mancia G
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S17-25. PubMed ID: 15868115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Type 2 diabetes and cardiovascular risk: lessons from therapeutic trials].
    Lièvre M
    Rev Prat; 2001 Oct; 51(16):1793-9. PubMed ID: 11795124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibiting the renin-angiotensin system: why and in which patients.
    Berra K; Miller NH
    J Am Acad Nurse Pract; 2009 Jan; 21(1):66-75. PubMed ID: 19125897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: Secondary medical prevention in patients with peripheral arterial disease.
    Schouten O; Welten GM; Bax JJ; Poldermans D
    Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):59-60. PubMed ID: 17719805
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
    J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
    Dahlöf B; Devereux RB; Kjeldsen SE; Lyle PA; Zhang Z; Edelman JM
    Blood Press; 2007; 16(1):6-12. PubMed ID: 17453746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The importance of managing cardiovascular risk in the treatment of hypertension: the role of ACE inhibitors and ARBs.
    Pierson CA; Epstein BJ; Roberts ME
    J Am Acad Nurse Pract; 2008 Nov; 20(11):529-38. PubMed ID: 19128336
    [No Abstract]   [Full Text] [Related]  

  • 11. Management of cardiovascular risk with RAS inhibitor/CCB combination therapy.
    Dahlöf B
    J Hum Hypertens; 2009 Feb; 23(2):77-85. PubMed ID: 18685606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of hypertension in peripheral arterial disease: does the choice of drugs matter?
    Singer DR; Kite A
    Eur J Vasc Endovasc Surg; 2008 Jun; 35(6):701-8. PubMed ID: 18375152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2.
    Bommer WJ
    Prev Cardiol; 2008; 11(4):215-22. PubMed ID: 19476574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving microvascular outcomes in patients with diabetes through management of hypertension.
    McGill JB
    Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective effects of renin-angiotensin blockade beyond blood pressure control.
    Mancia G; Giannattasio C; Seravalle G; Quarti-Trevano F; Grassi G
    J Hum Hypertens; 2009 Sep; 23(9):570-7. PubMed ID: 19190657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of hypertension in patients with chronic kidney disease and diabetes mellitus.
    Palmer BF
    Am J Med; 2008 Aug; 121(8 Suppl):S16-22. PubMed ID: 18638614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular disease risk factor assessment and management in gout: an analysis using guideline-based electronic clinical decision support.
    Colvine K; Kerr AJ; McLachlan A; Gow P; Kumar S; Ly J; Wiltshire C; Robinson E; Dalbeth N
    N Z Med J; 2008 Nov; 121(1285):73-81. PubMed ID: 19079439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood pressure-lowering drugs: essential therapy for some patients with normal blood pressure.
    Fuchs FD
    Expert Rev Cardiovasc Ther; 2004 Sep; 2(5):771-5. PubMed ID: 15350178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.